Research progress on the relationship between gut microbiota and its metabolites and hypertension

doi:10.3877/cma.j.issn.2095-655X.2025.02.010

Abstract

Abstract:

Hypertension is one of the most prevalent chronic diseases worldwide， with a continuously increasing incidence influenced by multiple factors， including environmental and genetic factors. Recent studies have demonstrated that gut microbiota and its metabolites play a crucial role in the pathogenesis and progression of hypertension. This review summarizes the relationship between gut microbiota， its metabolites，and hypertension， with a particular focus on gut microbiota-based prevention and treatment strategies，including probiotic supplementation， dietary regulation， antibiotic intervention， and fecal microbiota transplantation. Furthermore， future research directions are discussed to provide new insights into the precise management of hypertension.

Key words: Hypertension, Intestinal flora, Metabolite, Therapeutic

Hao Lyu, Fukai Qian, Rui Xu. Research progress on the relationship between gut microbiota and its metabolites and hypertension[J]. Chinese Journal of Diagnostics(Electronic Edition), 2025, 13(02): 126-132.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2025.02.010

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2025/V13/I02/126

References 82

［1］	Zhang M，Shi Y，Zhou B，et al.Prevalence，awareness，treatment，and control of hypertension in China，2004-18： findings from six rounds of a national survey［J］.BMJ，2023（380）：e071952.DOI：10.1136/bmj-2022-071952.
［2］	McEvoy JW，McCarthy CP，Bruno RM，et al.2024 ESC Guidelines for the management of elevated blood pressure and hypertension［J］.Eur Heart J，2024，45（38）：3912-4018.DOI：10.1093/eurheartj/ehae178.
［3］	O′Donnell JA，Zheng T，Meric G，et al.The gut microbiome and hypertension［J］.Nat Rev Nephrol，2023，19（3）：153-167.DOI：10.1038/s41581-022-00654-0.
［4］	Ahmad AF，Dwivedi G，O′Gara F，et al.The gut microbiome and cardiovascular disease：current knowledge and clinical potential［J］.Am J Physiol Heart Circ Physiol，2019，317（5）：H923-H938.DOI：10.1152/ajpheart.00376.2019.
［5］	Chen L，He FJ，Dong Y，et al.Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives：a randomized，double-blind，placebo-controlled trial［J］.Hypertension，2020，76（1）：73-79.DOI：10.1161/HYPERTENSIONAHA.120.14800.
［6］	Robles-Vera I，Toral M，de la Visitación N，et al.Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension：role of short-chain fatty acids［J］.Mol Nutr Food Res，2020，64（6）：e1900616.DOI：10.1002/mnfr.201900616.
［7］	Pluznick JL，Protzko RJ，Gevorgyan H，et al.Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation［J］.Proc Natl Acad Sci U S A，2013，110（11）：4410-4415.DOI：10.1073/pnas.1215927110.
［8］	Natarajan N，Hori D，Flavahan S，et al.Microbial short chain fatty acid metabolites lower blood pressure via endothelial G proteincoupled receptor 41［J］.Physiol Genomics，2016，48（11）：826-834.DOI：10.1152/physiolgenomics.00089.2016.
［9］	Kaye DM，Shihata WA，Jama HA，et al.Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease［J］.Circulation，2020，141（17）：1393-1403.DOI：10.1161/CIRCULATIONAHA.119.043081.
［10］	Rose S，Bennuri SC，Davis JE，et al.Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism［J］.Transl Psychiatry，2018，8（1）：42.DOI：10.1038/s41398-017-0089-z.
［11］	Wu Y，Xu H，Tu X，et al.The role of short-chain fatty acids of gut microbiota origin in hypertension［J］.Front Microbiol，2021（12）：730809.DOI：10.3389/fmicb.2021.730809.
［12］	Poll BG，Xu J，Jun S，et al.Acetate，a short-chain fatty acid，acutely lowers heart rate and cardiac contractility along with blood pressure［J］.J Pharmacol Exp Ther，2021，377（1）：39-50.DOI：10.1124/jpet.120.000187.
［13］	Ratajczak W，Rył A，Mizerski A，et al.Immunomodulatory potential of gut microbiome-derived short-chain fatty acids （SCFAs）［J］.Acta Biochim Pol，2019，66（1）：1-12.DOI：10.18388/abp.2018_2648.
［14］	Liu YJ，Tang B，Wang FC，et al.Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiotadependent manner［J］.Theranostics，2020，10（12）：5225-5241.DOI：10.7150/thno.43716.
［15］	Haghikia A，Jörg S，Duscha A，et al.Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine［J］.Immunity，2015，43（4）：817-829.DOI：10.1016/j.immuni.2015.09.007.
［16］	Bartolomaeus H，Balogh A，Yakoub M，et al.Short-chain fatty acid propionate protects from hypertensive cardiovascular damage［J］.Circulation，2019，139（11）：1407-1421.DOI：10.1161/CIRCULATIONAHA.118.036652.
［17］	Marques FZ，Nelson E，Chu PY，et al.High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice［J］.Circulation，2017，135（10）：964-977.DOI：10.1161/CIRCULATIONAHA.116.024545.
［18］	Hodgkinson K，El Abbar F，Dobranowski P，et al.Butyrate′s role in human health and the current progress towards its clinical application to treat gastrointestinal disease［J］.Clin Nutr （Edinb Scotl），2023，42（2）：61-75.DOI：10.1016/j.clnu.2022.10.024.
［19］	Guan Y，Chen K，Quan D，et al.The combination of scutellaria baicalensis georgi and sophora japonica l.ameliorate renal function by regulating gut microbiota in spontaneously hypertensive rats［J］.Front Pharmacol，2020（11）：575294.DOI：10.3389/fphar.2020.575294.
［20］	Kim S，Goel R，Kumar A，et al.Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure［J］.Clin Sci （Lond），2018，132（6）：701-718.DOI：10.1042/CS20180087.
［21］	Yang T， Rodriguez V， Malphurs WL， et al. Butyrate regulates inflammatory cytokine expression without affecting oxidative respiration in primary astrocytes from spontaneously hypertensive rats［J］.Physiol Rep，2018，6（14）：e13732.DOI：10.14814/phy2.13732.
［22］	Li Y，Zhou E，Yu Y，et al.Butyrate attenuates cold-induced hypertension via gut microbiota and activation of brown adipose tissue［J］.Sci Total Environ，2024（943）：173835.DOI：10.1016/j.scitotenv.2024.173835.
［23］	Yao L，Seaton SC，Ndousse-Fetter S，et al.A selective gut bacterial bile salt hydrolase alters host metabolism［J］.Elife，2018（7）：e37182.DOI：10.7554/eLife.37182.
［24］	Mistry RH，Verkade HJ，Tietge UJ.Reverse cholesterol transport is increased in germ-free mice-brief report［J］.Arterioscler Thromb Vasc Biol，2017，37（3）：419-422.DOI：10.1161/ATVBAHA.116.308306.
［25］	Jones BV，Begley M，Hill C，et al.Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome［J］.Proc Natl Acad Sci U S A，2008，105（36）：13580-13585.DOI：10.1073/pnas.0804437105.
［26］	Zhu Q，Zhu Y，Liu Y，et al.Moderation of gut microbiota and bile acid metabolism by chlorogenic acid improves high-fructoseinduced salt-sensitive hypertension in mice［J］.Food Funct，2022，13（13）：6987-6999.DOI：10.1039/d2fo00038e.
［27］	Ji CG，Xie XL，Yin J，et al.Bile acid receptor TGR5 overexpression is associated with decreased intestinal mucosal injury and epithelial cell proliferation in obstructive jaundice［J］.Transl Res，2017（182）：88-102.DOI：10.1016/j.trsl.2016.12.001.
［28］	Makishima M，Okamoto AY，Repa JJ，et al.Identification of a nuclear receptor for bile acids［J］.Science，1999，284（5418）：1362-1365.DOI：10.1126/science.284.5418.1362.
［29］	Gou X，Qin L，Wu D，et al.Research progress of takeda G proteincoupled receptor 5 in metabolic syndrome［J］.Molecules，2023，28（15）：5870.DOI：10.3390/molecules28155870.
［30］	Li C，Li J，Weng X，et al. Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats［J］.J Am Soc Hypertens，2015，9（7）：507-516.e7.DOI：10.1016/j.jash.2015.04.006.
［31］	Guo Y，Qiao R，Xie G，et al.Activation of TGR5 increases urine concentration by inducing AQP2 and AQP3 expression in renal medullary collecting ducts［J］.Kidney Dis （Basel），2024，10（3）：181-192.DOI：10.1159/000538107.
［32］	Shi H，Zhang B，Abo-Hamzy T，et al.Restructuring the gut microbiota by intermittent fasting lowers blood pressure［J］.Circ Res，2021，128（9）：1240-1254.DOI：10.1161/CIRCRESAHA.120.318155.
［33］	Yang K，Zhang P，Ding X，et al.Integrating bioinformatics and metabolomics to identify potential biomarkers of hypertensive nephropathy［J］.Sci Rep，2025，15（1）：7437.DOI：10.1038/s41598-025-89601-0.
［34］	Campbell C， McKenney PT， Konstantinovsky D， et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells［J］.Nature，2020，581（7809）：475-479.DOI：10.1038/s41586-020-2193-0.
［35］	Romano KA，Vivas EI，Amador-Noguez D，et al.Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide［J］.mBio，2015，6（2）：e02481.DOI：10.1128/mBio.02481-14.
［36］	Zeisel SH，Warrier M.Trimethylamine N-oxide，the microbiome，and heart and kidney disease［J］.Annu Rev Nutr，2017（37）：157-181.DOI：10.1146/annurev-nutr-071816-064732.
［37］	Liu Y，Dai M.Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation：new insights into atherosclerosis［J］.Mediators Inflamm，2020，2020（1）：4634172.DOI：10.1155/2020/4634172.
［38］	Ge X， Zheng L， Zhuang R， et al. The gut microbial metabolite trimethylamine n-oxide and hypertension risk：a systematic review and dose-response meta-analysis［J］.Adv Nutr，2020，11（1）：66-76.DOI：10.1093/advances/nmz064.
［39］	Jiang S，Shui Y，Cui Y，et al.Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension［J］.Redox Biol，2021（46）：102115.DOI：10.1016/j.redox.2021.102115.
［40］	Caradonna E，Abate F，Schiano E，et al.Trimethylamine-N-oxide（TMAO） as a rising-star metabolite：implications for human health［J］.Metabolites，2025，15（4）：220.DOI：10.3390/metabo15040220.
［41］	Liu M， Han Q， Yang J. Trimethylamine-N-oxide （TMAO）increased aquaporin-2 expression in spontaneously hypertensive rats［J］.Clin Exp Hypertens，2019，41（4）：312-322.DOI：10.1080/10641963.2018.1481420.
［42］	Liu G，Cheng J，Zhang T，et al.Inhibition of microbiota-dependent trimethylamine N-oxide production ameliorates high salt diet-induced sympathetic excitation and hypertension in rats by attenuating central neuroinflammation and oxidative stress［J］.Front Pharmacol，2022（13）：856914.DOI：10.3389/fphar.2022.856914.
［43］	Ufnal M，Jazwiec R，Dadlez M，et al.Trimethylamine-N-oxide：a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin Ⅱ in rats［J］.Can J Cardiol，2014，30（12）：1700-1705.DOI：10.1016/j.cjca.2014.09.010.
［44］	Huc T，Drapala A，Gawrys M，et al.Chronic，low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats［J］.Am J Physiol Heart Circ Physiol，2018，315（6）：H1805-H1820.DOI：10.1152/ajpheart.00536.2018.
［45］	王世杰，陈松.肠源性三甲胺生成机制及其饮食调控［J］.食品科学技术学报，2023，41（1）：22-29.DOI：10.12301/spxb202200301.
［46］	Jang JW，Capaldi E，Smith T，et al.Trimethylamine N-oxide：a meta-organismal axis linking the gut and fibrosis［J］.Mol Med，2024，30（1）：128.DOI：10.1186/s10020-024-00895-8.
［47］	Xiao L，Dong JH，Teng X，et al.Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling［J］.J Hypertens，2018，36（3）：651-665.DOI：10.1097/HJH.0000000000001605.
［48］	Donertas Ayaz B，Oliveira AC，Malphurs WL，et al.Central administration of hydrogen sulfide donor NaHS reduces Iba1-positive cells in the PVN and attenuates rodent angiotensin II hypertension［J］.Front Neurosci，2021（15）：690919.DOI：10.3389/fnins.2021.690919.
［49］	Weber GJ， Pushpakumar S， Tyagi SC， et al. Homocysteine and hydrogen sulfide in epigenetic，metabolic and microbiota related renovascular hypertension［J］.Pharmacol Res，2016，113（Pt A）：300-312.DOI：10.1016/j.phrs.2016.09.002.
［50］	Tomasova L，Dobrowolski L，Jurkowska H，et al.Intracolonic hydrogen sulfide lowers blood pressure in rats［J］.Nitric Oxide：Biol Chem，2016（60）：50-58.DOI：10.1016/j.niox.2016.09.007.
［51］	Huc T， Jurkowska H， Wróbel M， et al. Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats［J］.Exp Biol Med （Maywood），2018，243（1）：96-106.DOI：10.1177/1535370217741869.
［52］	Mu YF，Gao ZX，Mao ZH，et al.Perspectives on the involvement of the gut microbiota in salt-sensitive hypertension［J］.Hypertens Res：Off J Jpn Soc Hypertens，2024，47（9）：2351-2362.DOI：10.1038/s41440-024-01747-y.
［53］	Verhaar BJH，Prodan A，Nieuwdorp M，et al.Gut microbiota in hypertension and atherosclerosis：a review［J］.Nutrients，2020，12（10）：2982.DOI：10.3390/nu12102982.
［54］	Kaminsky LW，Al-Sadi R，Ma TY.IL-1β and the intestinal epithelial tight junction barrier［J］.Front Immunol，2021（12）：767456.DOI：10.3389/fimmu.2021.767456.
［55］	张兴宇，徐磊，卡德尔业·卡德尔，等.田蓟苷下调TLR4/Myd88/NF-κB信号通路抑制NLRP3炎症小体和炎症反应［J］.药学学报，2024，59（7）：2012-2019.DOI：10.16438/j.0513-4870.2024-0228.
［56］	Elijovich F，Laffer CL，Sahinoz M，et al.The gut microbiome，inflammation，and salt-sensitive hypertension［J］.Curr Hypertens Rep，2020，22（10）：79.DOI：10.1007/s11906-020-01091-9.
［57］	Grylls A，Seidler K，Neil J.Link between microbiota and hypertension：focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation，and therapeutic implication of probiotics［J］.Biomed Pharmacother，2021（137）：111334.DOI：10.1016/j.biopha.2021.111334.
［58］	Chai X，Liu L，Chen F.Oral nitrate-reducing bacteria as potential probiotics for blood pressure homeostasis［J］.Front Cardiovasc Med，2024（11）：1337281.DOI：10.3389/fcvm.2024.1337281.
［59］	Upadrasta A， Madempudi RS. Probiotics and blood pressure：current insights［J］.Integr Blood Press Control，2016（9）：33-42.DOI：10.2147/IBPC.S73246.
［60］	Wilck N， Matus MG， Kearney SM， et al. Salt-responsive gut commensal modulates TH17 axis and disease［J］.Nature，2017，551（7682）：585-589.DOI：10.1038/nature24628.
［61］	唐曼玉，王晚晴，强敬雯，等.益生菌与肠道菌群、免疫调节的相互作用与机制研究进展［J］.食品工业科技，2022，43（16）：486-493.DOI：10.13386/j.issn1002-00306.2022030025.
［62］	Yuan L，Li Y，Chen M，et al.Effects of probiotics on hypertension［J］.Appl Microbiol Biotechnol，2023，107（4）：1107-1117.DOI：10.1007/s00253-023-12369-8.
［63］	Hadi A， Pourmasoumi M， Kazemi M， et al. Efficacy of synbiotic interventions on blood pressure：a systematic review and metaanalysis of clinical trials［J］.Crit Rev Food Sci Nutr，2022，62（20）：5582-5591.DOI：10.1080/10408398.2021.1888278.
［64］	Wang W，Li Y，Han G，et al.Lactobacillus fermentum CECT5716 alleviates the inflammatory response in asthma by regulating TLR2/TLR4 expression［J］.Front Nutr，2022（9）：931427.DOI：10.3389/fnut.2022.931427.
［65］	孙鹏伟，皇甫卫忠.肠道菌群与高血压关系的研究进展［J］.疑难病杂志，2024，23（6）：751-755，768.DOI：10.3969/j.issn.1671-6450.2024.06.021.
［66］	Zhao TX，Zhang L，Zhou N，et al.Long-term use of probiotics for the management of office and ambulatory blood pressure：a systematic review and meta-analysis of randomized，controlled trials［J］.Food Sci Nutr，2023，11（1）：101-113.DOI：10.1002/fsn3.3069.
［67］	Rahman MdM，Islam F，-Or-Rashid MdH，et al.The gut microbiota（microbiome） in cardiovascular disease and its therapeutic regulation［J］.Front Cell Infect Microbiol，2022（12）：903570.DOI：10.3389/fcimb.2022.903570.
［68］	Aljuraiban GS，Gibson R，Chan DSM，et al.The role of diet in the prevention of hypertension and management of blood pressure：an umbrella review of meta-analyses of interventional and observational studies［J］.Adv Nutr，2023，15（1）：100123.DOI：10.1016/j.advnut.2023.09.011.
［69］	Reynolds AN，Akerman A，Kumar S，et al.Dietary fibre in hypertension and cardiovascular disease management：systematic review and meta-analyses［J］.BMC Med，2022，20（1）：139.DOI：10.1186/s12916-022-02328-x.
［70］	肖礼其，杨莉，崔赛仙，等.高盐诱导肠道菌群紊乱调节盐敏感性血压的机制研究［J］.中国全科医学，2023，26（29）：3704-3709.DOI：10.12114/j.issn.1007-9572.2022.0448.
［71］	Elijovich F，Kleyman TR，Laffer CL，et al.Immune mechanisms of dietary salt-induced hypertension and kidney disease：harry goldblatt award for early career investigators 2020［J］.Hypertension，2021，78（2）：252-260.DOI：10.1161/HYPERTENSIONAHA.121.16495.
［72］	Yan X，Jin J，Su X，et al.Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension［J］.Circ Res，2020，126（7）：839-853.DOI：10.1161/CIRCRESAHA.119.316394.
［73］	Kim H，Lichtenstein AH，Coresh J，et al.Serum protein responses to dietary approaches to stop hypertension （DASH） and DASHsodium trials and associations with blood pressure changes［J］.J Hypertens，2024，42（10）：1823-1830.DOI：10.1097/HJH.0000000000003828.
［74］	Filippou CD，Tsioufis CP，Thomopoulos CG，et al.Dietary Approaches to Stop Hypertension （DASH） diet and blood pressure reduction in adults with and without hypertension：a systematic review and metaanalysis of randomized controlled trials［J］.Adv Nutr，2020，11（5）：1150-1160.DOI：10.1093/advances/nmaa041.
［75］	Barton W，Penney NC，Cronin O，et al.The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level［J］.Gut，2018，67（4）：625-633.DOI：10.1136/gutjnl-2016-313627.
［76］	Clarke SF，Murphy EF，O'Sullivan O，et al.Exercise and associated dietary extremes impact on gut microbial diversity［J］.Gut，2014，63（12）：1913-1920.DOI：10.1136/gutjnl-2013-306541.
［77］	Yang T，Santisteban MM，Rodriguez V，et al.Gut dysbiosis is linked to hypertension［J］.Hypertension，2015，65（6）：1331-1340.DOI：10.1161/HYPERTENSIONAHA.115.05315.
［78］	Galla S，Chakraborty S，Cheng X，et al.Exposure to amoxicillin in early life is associated with changes in gut microbiota and reduction in blood pressure：findings from a study on rat dams and offspring［J］.J Am Heart Assoc，2020，9（2）：e014373.DOI：10.1161/JAHA.119.014373.
［79］	Galla S，Chakraborty S，Cheng X，et al.Disparate effects of antibiotics on hypertension［J］.Physiol Genomics，2018，50（10）：837-845.DOI：10.1152/physiolgenomics.00073.2018.
［80］	Yoo HH，Kim IS，Yoo DH，et al.Effects of orally administered antibiotics on the bioavailability of amlodipine：gut microbiota-mediated drug interaction［J］.J Hypertens，2016，34（1）：156-162.DOI：10.1097/HJH.0000000000000773.
［81］	Adnan S，Nelson JW，Ajami NJ，et al.Alterations in the gut microbiota can elicit hypertension in rats［J］.Physiol Genomics，2017，49（2）：96-104.DOI：10.1152/physiolgenomics.00081.2016.
［82］	Li J，Zhao F，Wang Y，et al.Gut microbiota dysbiosis contributes to the development of hypertension［J］.Microbiome，2017，5（1）：14.DOI：10.1186/s40168-016-0222-x.

[1]	Juan Yang, Xue Du, Wang Tian, Wenjie Lyu, Yuanyuan Yang, Zongzhi Yin. Efficacy analysis of uterine artery embolization in the treatment of retained placenta by dilation and curettage for patients with retained placenta and patients with retained placenta complicated with placenta accreta after vaginal delivery [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2025, 21(01): 114-121.
[2]	Xiwen Yan, Huiyuan Liu. Pathogenesis and prevention strategy of end-stage liver disease complicated with infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2025, 19(01): 39-43.
[3]	Chengjun Yu, Jie Zhang, Jun Pei, Fansen Kong, Shuyuan Yang, Shengde Wu, Xing Liu, Sheng Wen, Yi Hua, Guanghui Wei. Clinical characteristics and efficacy of kidney transplantation in children with end-stage renal disease [J]. Chinese Journal of Transplantation(Electronic Edition), 2025, 19(01): 31-35.
[4]	Hongzhou Zhao, Guoxian Wei, Long Liu, Nianbin Yang, Dan Li. Comparison of the therapeutic effects and recurrence rates between laparoscopic hernia repair and traditional hernia repair in the treatment of inguinal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(01): 79-82.
[5]	Fei Jia, Quanwu Zhang, Yu Gao, Chao Xin. Clinical analysis of sputum lipoarabinomannan in predicting the effectiveness of pulmonary tuberculosis treatment [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 74-79.
[6]	Yang Shi, Hui Guo, Jian Li. TIPS standard procedures and management of surgery-related complications for portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(03): 372-378.
[7]	Weinan Li, Gang Yang, Yongfu Xiong, Qiang Li, Jingdong Li. Preliminary experience of ALPPS after TACE combined with targeted immunotherapy for middle stage and advanced liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 97-101.
[8]	Junfu Chen, Jixia Wu, Hongliang Tian, Jing Ma. FMT in microbiota-gut-brain axis disorders：therapeutic advances [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(02): 136-141.
[9]	Weifeng Shang, Dechang Chen. Investigating new targets for the treatment of sepsis-associated encephalopathy based on gut microbiota [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2025, 11(01): 31-35.
[10]	Zhen Chen, Tianlei Yu, Xiaochao Liu, Meng Yin. Changes of blood cell parameters，renal function and nutritional score and their correlation with prognosis in cirrhotic patients with portal hypertension and acute upper gastrointestinal hemorrhage [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(02): 149-154.
[11]	Baojing Du, Minye Li, Yunxia Wang, Yongjing Shen, Weiwei Tan. Relationship between intestinal flora characteristics and serum zinc, CK-MB and inflammatory factors in children with rotavirus infection-related diarrhea [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 78-82.
[12]	Shuangxing Wang, Yongjie Wu, Bing Meng, Hongtao Zhang, Dan Wei, Hui Zhang, Mei Diao. Risk factors for delayed postoperative recovery in infants with non-restrictive ventricular septal defect [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(03): 188-193.
[13]	Baiping Sun, Xin Xu, Quan Xu, Yiping He, Juanjuan Zhang, Jin Dong. Clinical study on spontaneous splenic rupture during pregnancy [J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2025, 14(02): 102-105.
[14]	Jinzhi Wang, Yifan Wu, Xincao Tao, Wanmu Xie, Shuai Zhang, Yunxia Zhang, Zhu Zhang, Yu Zhang, Jixiang Liu, Linfeng Xi, Yishan Li, Qian Gao, Qiang Huang, Zhenguo Zhai. The assessment value of fractional flow reserve for hemodynamics in patients with chronic thromboembolic pulmonary hypertension [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2025, 13(01): 18-22.
[15]	Yao Deng, Bicheng Xie, Bian Wu, Danfeng Lan. Research progress on the effect of bariatric surgery on intestinal flora and metabolic inflammatory syndrome [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 70-75.

Please choose a citation manager

Content to export